

# Electronic Supplementary Information

## Host-guest complexation of oxaliplatin and *para*-sulfonatocalix[n]arenes for potential use in cancer therapy

Sherif Ashraf Fahmy<sup>1</sup>, Fortuna Ponte<sup>2</sup>, Iten M. Fawzy<sup>3</sup>, Emilia Sicilia<sup>2</sup>, Udo Bakowsky<sup>4\*</sup> and Hassan M. E. Azzazy<sup>1\*</sup>




<sup>1</sup>Department of Chemistry, School of Sciences & Engineering, The American University in Cairo, AUC Avenue, PO. Box 74, New Cairo 11835, Egypt; sheriffahmy@aucegypt.edu

<sup>2</sup> Department of Chemistry and Chemical Technologies, University of Calabria, Arcavacata di Rende, 87036, Italy


<sup>3</sup>Pharmaceutical Chemistry Department, Faculty of Pharmaceutical Sciences and Pharmaceutical Industries, Future University in Egypt, Cairo 12311, Egypt; iten.mamdouh@fue.edu.eg

<sup>4</sup> Department of Pharmaceutics and Biopharmaceutics, University of Marburg, Robert- Koch-Str. 4, 35037 Marburg, Germany.

\* Correspondence: ubakowsky@aol.com (U.B.); [hazzazy@aucegypt.edu](mailto:hazzazy@aucegypt.edu) (H.M.E.-S.A.); Tel.: +49-(0)-6421-28-2-58-84 (U.B.); +2 02 2615 2559; Fax: +2 02 2795 7565 (H.M.E.-S.A.)

**A****B****C**

**Figure S1.**  $^1\text{H}$ NMR spectra of (A) *p*-SC4 alone, (B) oxaliplatin alone, and (C) equimolar ratio of amount of oxaliplatin and *p*-SC4. Structures of oxaliplatin and *p*-SC4 are shown with appropriate protons labeled.



**Figure S2** First derivative of ratio spectra of the mixtures containing successively increasing concentrations of oxaliplatin (ranging from 0.01-0.21 mM) and a fixed concentration of 0.2 mM *p*-SC4 all in distilled water using the spectrum of 0.2 mM of *p*-SC4 as a divisor.


**Table S1.** ADMET study results of oxaliplatin, oxaliplatin/*p*-SC4, and oxaliplatin/*p*-SC6 complexes as performed by Discovery Studio 4.0.

ADMET values and descriptors are provided below.


	Aqueous Solubility Level	Human Intestinal Absorption	Hepatotoxicity	CYP-2D6	BBB (Blood Brain Barrier Penetration Level)	PPB (Plasma Protein Binding)
Oxaliplatin	3	0	1	0	3	0
Oxaliplatin/ <i>p</i> -SC4	5	3	1	0	4	1
Oxaliplatin/ <i>p</i> -SC6	5	3	1	0	4	1

**Discovery Studio 4.0 ADMET values and descriptors**

Discovery Studio 4.0 Descriptors	Aqueous Solubility Level			Human Intestinal Absorption		Hepatotoxicity		CYP-2D6		BBB (Blood Brain Barrier Penetration Level)		PPB (Plasma Protein Binding)	
	Level	Value	Description	Level	Description	Level	Description	Level	Description	Level	Description	Level	Description
	0	log (molar solubility) < -8.0	Extremely low	0	Good absorption	0	Non-toxic	0	Non-inhibitor	0	Very High	0	Binding is <90%
	1	-8.0 < log (molar solubility) < -6.0	No, very low, but possible										
	2	-6.0 < log (molar solubility) < -4.0	Yes, low	1	Moderate absorption					1	High		
	3	-4.0 < log (molar solubility) < -2.0	Yes, good			2	Medium						
	4	-2.0 < log (molar solubility) < 0.0	Yes, optimal	2	Low absorption	1	Toxic	1	Inhibitor	3	Low	1	Binding is ≥90%
	5	0.0 < log (molar solubility)	No, too soluble							4	Undefined		
	6	-1000	Warning: molecules with one or more unknown AlogP98 types	3	Very Low absorption					5	Warning: molecules with one or more unknown AlogP calculation	2	Binding is ≥95%



**Figure S3.** The shift in the biological properties between oxaliplatin alone and oxaliplatin/p-SC4 complex.



**Figure S4.** The shift in the biological properties between oxaliplatin alone and oxaliplatin in complex with SC6-calixarene.





